Subscribe
pills-istock-499257708-stock-colors
stock_colors / iStockphoto.com
21 February 2017Americas

DoJ sues company for selling unapproved drugs and supplements

The US Department of Justice (DoJ) has asked for an injunction to stop a Louisiana-based drug and dietary supplement manufacturer from distributing misbranded and unapproved new drugs and dietary supplements.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.

More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers